To study the cost-effectiveness of a population-wide, pneumococcal vaccination program in Malaysian children with the 13-valent pneumococcal conjugate vaccine (PCV13) versus the 10-valent pneumococcal conjugate vaccine (PCV10)
Objective
To study the cost-effectiveness of a population-wide, pneumococcal vaccination program in Malaysian children with the 13-valent pneumococcal conjugate vaccine (PCV13) versus the 10-valent pneumococcal conjugate vaccine (PCV10)
Background
Infectious caused by Streptococcus pneumoniae is one of the major causes of death of children under the age of five. There are currently two pneumococcal conjugated vaccines in Malaysia. However, pneumococcal vaccination is not currently part of the national immunization program (NIP). The cost effectiveness and public health impact of NIP using either vaccine has not been previously studied.
Methods
•A 10-year Markov model as shown in Figure 1 .0, developed by i3 Innovus was used.
• Analysis was conducted based on payer's perspective.
•Cost were calculated based on drug acquisition cost as well as direct medical costs only.
•3% discount rate was applied to both costs and outcomes.
•Both direct and indirect effects of the vaccines on disease prevention were considered in the analysis
PIN46 Results

Efficacy
•Additional cases of pneumococcal diseases that could be avoided with PCV13 versus PCV10 (over a 10 year period) were as below:
•IPD: 9,681 cases •Hospitalized pneumonia: 400,678 cases •Non-hospitalized pneumonia: 1,005,034 cases •Comparing PCV 13 versus PCV10, cases of hospitalized otitis media (complex otitis media) that could be avoided among children < 5 years old was 82,847 cases.
•Death averted with the implementation of NIP with PCV13 versus PCV10 from IPD was 2,184 cases and also 18,275 cases from hospitalized pneumonia.
Costs
•Due to the higher acquisition cost for PCV13, an additional RM10,056 million is needed for the vaccination program over a 10-year period.
•PCV 13 can potentially lead to RM1,406 million savings in direct medical cost compared to PCV10.
•Majority of the cost savings would occur in children < 5 years old. (Table  1 .0)
Cost-effectiveness analysis
•Total life-year saved was 562,180, while total QALYs gained was 514,573
•Cost per life-year saved was at RM15,385 while cost per QALY gained was Model input:
•Population size was about 28 million (Year 2011). 1 •Local and regional epidemiology data were used when possible. 2, 3, 4, 5, 6, 7, 8 •Outpatient visits for pneumonia were estimated from reported incidence of inpatient pneumonia with an age based coefficient derived from the ratio of outpatient/ inpatient visits in United States (US). 9, 10, 11 •Using the ratio of outpatient/ inpatient AOM cases in US as a reference, incidences of outpatient AOM were assumed to be 5 times that of complex AOM. 9, 12 •PCV 13 and PCV 10 effectiveness was extrapolated from PCV7 data, taking into consideration the local serotype distribution. 13 • Medical and vaccine costs were obtained from local sources while lifetime medical costs of disability were estimated from US data. 9 •The additional protection from non-typeable H. influenzae with PCV10 was capped at 4% for complex otitis media in children <23 months. 14 
Conclusion
•Based on the present analysis, PCV13 appears to be a more cost-effective alternative in a NIP ISPOR, 14 th Annual European Congress, Madrid, 2011
Assumptions
•The analysis assumed a 3-dose vaccine series •96% vaccine coverage for both PCV13 and PCV 10 •The private market acquisition cost for the vaccines was used •The model assumed a lower immunogenic response for PCV10 relative to PCV13 . 15, 16 •Based on experience with the 7-valent pneumococcal vaccine, it was assumed that no cross-reactivity occurs for PCV10 with serotypes 6B and 6A as well as 19F and 19A. 17 g at RM16,809.
Sensitivity Analysis
•Deterministic sensitivity analysis showed that incidences of nonhospitalized pneumonia was an important factor in determining life-year saved.
•Incidences of hospitalized pneumonia is the most sensitive factor in determining potential cost savings, followed by the medical cost of hospitalized pneumonia. (Figure 2 .0) 
